Inclusion Criteria:

- All adults with first remission AML including those with prior myelodysplasia
(MDS)/AML, therapy-related AML, AML with trilineage dysplasia (AML-TLD), and AML with
adverse cytogenetics

- History of histopathologically documented AML that is currently in first remission
with the presence of 5% or less blasts by morphology and/or flow cytometry from a
bone marrow aspirate and/or biopsy obtained within 14 days of enrollment

- Patients must start therapy between 3-8 weeks after receiving their last prior
therapy (either induction therapy or consolidation therapy)

- Patients may receive up to 4 courses of remission consolidation therapy (e.g.,
cytarabine) prior to enrollment

- Normal kidney and liver function with serum creatinine =< 2.0 mg/dl

- Total bilirubin =< 1.5 upper limit of normal (ULN)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

- Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree
to 1 of the following: practice effective barrier contraception during the entire
study treatment period and through a minimum of 30 days after the last dose of study
drug, or completely abstain from heterosexual intercourse

- Female subject is either postmenopausal for at least 1 year before the screening
visit, is surgically sterilized or if they are of childbearing potential, agree to
practice 2 effective methods of contraception from the time of signing the informed
consent form through 30 days after the last dose of bortezomib, or agree to
completely abstain from heterosexual intercourse

- Understand and voluntarily sign the informed consent form for this study

Exclusion Criteria:

- Favorable AML features defined as the following:

- t(8;21)(q22;q22); RUNX1-RUNX1T1

- inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

- Mutated NPM1 without FLT3-ITD (normal karyotype)

- Mutated CEBPA (normal karyotype)

- Persistent clinically significant non-hematological toxicity that is > Grade 1 by
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
v4 from prior chemotherapy

- Active uncontrolled infection

- Known infection with human immunodeficiency virus (HIV)

- Medical condition, serious concurrent illness, or other extenuating circumstance
that, in the judgment of the Principal Investigator, could jeopardize patient safety
or interfere with the objectives of the study

- Uncontrolled or significant cardiovascular disease, including:

- Uncontrolled angina or myocardial infarction within 6 months

- Current or history of congestive heart failure New York Heart Association (NYHA)
class 3 or 4, unless a screening echocardiogram (ECHO) or Multiple Gate
Acquisition Scan (MUGA) performed within 1 month prior to study screening
results in a left ventricular ejection fraction (LVEF) that is >= 45% (or
institutional lower limit of normal value)

- Prolonged QTc interval (> 450 msec)

- Diagnosed or treated for another malignancy within 3 years of enrollment, with the
exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy

- Patient has a platelet count of < 30,000 within 3 days before enrollment

- Patient has an absolute neutrophil count of < 300 within 3 days before enrollment

- Patient has >= Grade 2 peripheral neuropathy

- Patient has hypersensitivity to bortezomib, boron, or mannitol

- Female patients who are lactating or have a positive urine pregnancy test during the
screening; pregnancy testing is not required for postmenopausal or surgically
sterilized women

- Participation in clinical trials with other investigational agents not included in
this trial, within 14 days of the start of this trial and throughout the duration of
this trial